Fig. 1: MITF expression in melanoma patients treated with targeted and immunotherapy.
From: Fragment-based discovery enables direct targeting of the melanoma oncogene MITF
a, b Distribution of MITF expression at baseline in patients of the COMBI-i trial treated with Tafinlar® (anti-BRAF inhibitor Dabrafenib) and Mekinist® (anti-MEK inhibitor Trametinib), used as dual agent (a) or as triple combination with Spartalizumab® (anti-PD-1 inhibitor PDR001)23,24 (b). Patients are grouped based on clinical responses (according to the RECIST criteria). MITF expression is referenced to levels detected in the GTEx cohort of normal skin tissues (dotted line and gray plot). Sample sizes: a, CR = 33, PR = 92, SD = 40, PD = 18; b, CR = 38, PR = 99, SD = 25, PD = 17; GTEx = 661. Abbreviations: CR, complete response (dark blue); PR, partial response (light blue); SD, stable disease (light red); PD, progressive disease (dark red). c Heatmap representation of MITF and AXL transcriptional programs, based on published signatures25, in matched pair samples from 9 patients of the COMBI-i trial, treated with the triple combination of BRAF, MEK, and PD1 inhibitors. d MITF expression distribution at single-cell level in melanoma tumors collected either before (left) or after (right) treatment with an anti-PD1 inhibitor26. ICI, immune-checkpoint inhibitor.
